American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1381)
  9. Gastrointestinal Oncology Service (1356)
  10. Hematologic Malignancies, Division of (1286)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2591)
  3. Editorial (79)
  4. Review (70)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (308)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (303)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8712)
  2. JCO Precision Oncology (174)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (54)
  6. JCO Oncology Practice (12)

More Publications

Results (9195)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)
    Meeting Abstract

    Razavi, P.; Cabel, L.; Teysir, J.; An, J. A. R.; Rivero-Hinojosa, S.; Satta, S.; Bristow, S. L.; Kalashnikova, E.; Rodriguez, A. A.; Liu, M. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors
    Meeting Abstract

    Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study
    Meeting Abstract

    Mayer, E. L.; Miller, K.; Jhaveri, K. L.; Yeh, R.; Sakach, E.; Prasad, V.; Ferreira, D. V.; Herszdorfer, P.; Gong, L.; Li, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A.; Garofalo, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer
    Meeting Abstract

    Hutcheson, K. A.; Fuller, C. D.; Pytynia, K. B.; Hope, A. J.; Ringash, J.; Thorpe, K.; Palma, D. A.; Theurer, J.; Mills, G.; Cracchiolo, J. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816
    Meeting Abstract

    Forde, P. M.; Spicer, J.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C.; Lu, S.; Felip, E.; Broderick, S.; Swanson, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Wang, P.; Ellis, J.; Bar, M.; Kumar, J.; Farazi, T. A.; Garcia-Sancho, A. M.; Izutsu, K.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results
    Meeting Abstract

    Mar, N.; Petrylak, D. P.; Hoimes, C. J.; Rosenberg, J. E.; Flaig, T. W.; Gourdin, T. S.; Barata, P. C.; Henry, E.; Bilen, M. S.; George, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy
    Meeting Abstract

    Schwartz, L. H.; Akin, O.; Gold, S.; Deng, Y.; Lema-Dopico, A.; Chahwan, S.; Nincevic, J.; Ruby, L.; Capanu, M.; Apte, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save